Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments
• Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biology
• Reveals future prospects for developing precision medicines to modulate macrophages for the treatment of cancer by targeting tumour associated macrophage (TAMs) in the tumour microenvironment (TME)
Edinburgh and Cambridge, UK, 17 February 2023 – The founding scientists behind…
We are delighted to announce that we have entered into a Strategic Partnership for the Development and cGMP Manufacturing Services for Vaccitech’s Adenoviral Vector programme. Pharmaron will become a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform.
The partnership began last year with the technology transfer of a Vaccitech proprietary manufacturing process into Pharmaron’s state-of-the-art Liverpool viral development and GMP manufacturing facilities. This will enable Pharmaron to support…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
- Eighth new technology partnership with major pharmaceutical and biotech companies since IPO
Cambridge, UK, 14 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022.
Under the terms…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS
- Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics
Cambridge, UK, 16 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce…
The new MagSi-DNA FFPE kit from AMSBIO enables quick and easy isolation of genomic DNA (gDNA) from mammalian formalin-fixed paraffin-embedded (FFPE) tissue or cell samples.
Developed using proprietary magnetic bead technology – the MagSi-DNA FFPE kit can be used for manual and automated isolation of gDNA from mammalian FFPE tissue or cell samples.
The kit does not require traditional phenol/chloroform extraction or alcohol precipitation steps and also eliminates the need for repeated centrifugation, vacuum filtration or column separations. As a result, following paraffin removal and lysis…
India stands as a promising power in the pharmaceutical industry
The Asian country is growing the pharmaceutical industry at an unprecedented rate and DIVERSA wants to join the challenge! India is currently experiencing a significant economic growth. In fact, although in the past it was not among the top 5 main world economic powers, it is estimated that it will occupy the third position by 2030. This forecast is based on its important role in the global pharmaceutical industry, among other reasons. DIVERSA has had the opportunity to meet relevant players in the Indian biotech sector and to…
Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases
Cambridge and Cardiff, UK, 13 February 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (“MDI”) announced today that they have entered into a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat…
February 11th marks International Day of Women and Girls in science, the purpose of which is to promote the ‘full and equal access and participation of females in STEM’.
According to United Nations, “Gender equality, besides being a fundamental human right, is essential to achieve peaceful societies, with full human potential and sustainable development.”
Gender diversity in science can have many advantages, yet organisations continue to lag behind in female representation. But the truth is, we need more girls and women in science, so we must explore how these gender differences can be better…
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
● Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK
● Joins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at Galderma, AstraZeneca and SCYNEXIS
● Will be responsible for developing NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore as treatments for Parkinson's…